Our group demonstrates TET2 delays nasopharyngeal carcinoma progression by interacting with PKM and suppressing glycolysis, suggesting that TET2 may serve as a new therapeutic target for NPC. Here, TET2 is linked to nasopharyngeal carcinoma.